SAN

82.76

-0.81%↓

MRK1

109.8

+0.23%↑

SHL.DE

46.12

+0.28%↑

ARGX

481

-1.13%↓

FRE

41.43

-1.12%↓

SAN

82.76

-0.81%↓

MRK1

109.8

+0.23%↑

SHL.DE

46.12

+0.28%↑

ARGX

481

-1.13%↓

FRE

41.43

-1.12%↓

SAN

82.76

-0.81%↓

MRK1

109.8

+0.23%↑

SHL.DE

46.12

+0.28%↑

ARGX

481

-1.13%↓

FRE

41.43

-1.12%↓

SAN

82.76

-0.81%↓

MRK1

109.8

+0.23%↑

SHL.DE

46.12

+0.28%↑

ARGX

481

-1.13%↓

FRE

41.43

-1.12%↓

SAN

82.76

-0.81%↓

MRK1

109.8

+0.23%↑

SHL.DE

46.12

+0.28%↑

ARGX

481

-1.13%↓

FRE

41.43

-1.12%↓

Search

Orion Oyj (Class B)

Suletud

65.95 -0.45

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

65.9

Max

66.95

Põhinäitajad

By Trading Economics

Sissetulek

-12M

61M

Müük

-80M

355M

P/E

Sektori keskmine

25.565

39.564

Aktsiakasum

0.44

Dividenditootlus

2.57

Kasumimarginaal

17.287

Töötajad

3,943

EBITDA

202M

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.57%

2.40%

Turustatistika

By TradingEconomics

Turukapital

3.4B

8.9B

Eelmine avamishind

66.4

Eelmine sulgemishind

65.95

Orion Oyj (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. juuli 2025, 22:07 UTC

Suurimad hinnamuutused turgudel

Trade Desk Rises on S&P 500 Inclusion

14. juuli 2025, 17:06 UTC

Suurimad hinnamuutused turgudel

Crypto Assets Rally Ahead of Possible U.S. Legislation

14. juuli 2025, 16:47 UTC

Omandamised, ülevõtmised, äriostud

NatWest to Sell Stake in Permanent TSB

14. juuli 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14. juuli 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14. juuli 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14. juuli 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14. juuli 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14. juuli 2025, 23:02 UTC

Tulu

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14. juuli 2025, 23:02 UTC

Tulu

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14. juuli 2025, 23:02 UTC

Tulu

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14. juuli 2025, 23:01 UTC

Tulu

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14. juuli 2025, 23:01 UTC

Tulu

China Vanke Expects 1H Loss to Widen >000002.SZ

14. juuli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. juuli 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14. juuli 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14. juuli 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14. juuli 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14. juuli 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14. juuli 2025, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14. juuli 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14. juuli 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. juuli 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14. juuli 2025, 16:53 UTC

Kuumad aktsiad

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14. juuli 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14. juuli 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

14. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. juuli 2025, 16:12 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Orion Oyj (Class B) Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.